Antibody Reduces Inflammation in Rheumatoid Arthritis

SUMMARY: Scientists have obtained data showing that an anti- properdin (a protein that participates in the destruction of bacteria) monoclonal antibody (MoAb) is effective at reducing inflammation in a rabbit model of immune complex deposition.The presence of immune complexes in the body has been suggested to lead to inflammatory conditions such as rheumatoid arthritis. Properdin is a protein of the complement alternative pathway, which along with the complement classical pathway serves as a host immune defense system. Inappropriate activation of complement has been shown to contribute to both acute and chronic disease pathologies, including those arising from rheumatoid arthritis. Taking MoAb could help reduce inflammation. CLEVELAND, March 20 /PRNewswire/ — Gliatech Inc. announced today that company scientists have obtained data showing that an anti- properdin monoclonal antibody (MoAb) is effective at reducing inflammation in a rabbit model of immune complex deposition. The presence of immune complexes in the body has been suggested to lead to inflammatory conditions such as rheumatoid arthritis, lupus and nephritis.Properdin is a protein of the complement alternative pathway, which along with the complement classical pathway serves as a host immune defense system. Inappropriate activation of complement has been shown to contribute to both acute and chronic disease pathologies, including those arising from cardiopulmonary bypass surgery, myocardial infarction, stroke, rheumatoid arthritis and lupus. Gliatech has developed proprietary MoAbs to properdin that are potent inhibitors of the complement alternative pathway. By blocking the alternative pathway, the majority of the negative consequences of inappropriate complement activation can be attenuated while leaving certain aspects of the classical complement pathway available for normal host immune defense. The company has previously shown that its anti-properdin MoAbs effectively block complement activation in models of cardiopulmonary bypass surgery. In the present study, an anti-properdin MoAb was shown to dramatically reduce inflammation in rabbits that are induced to develop dermal immune complexes. This inflammation model mimics certain aspects of rheumatoid arthritis. The company recently announced that it has entered into a research collaboration with Abgenix Inc. to develop fully human anti-properdin MoAbs for use in clinical settings where inappropriate complement activation contributes to disease onset or progression. “This recent data further supports our premise that activation of the complement alternative pathway contributes to a variety of disease states,” said Thomas O. Oesterling, Chairman and Chief Executive Officer of Gliatech Inc. “We are excited about the clinical and commercial potential of our anti- properdin monoclonal antibodies.” Gliatech is a leader in the discovery and development of therapeutic products based on the properties of glial (comprising neuroglia – supporting tissue intermingled with elements of nervous tissue) cells. The Company applies its core glial research to developing innovative products for major unmet human health care needs. Current development initiatives are targeting products to improve surgical outcomes and to treat neurological disorders. Source: Gliatech Inc.,

1 Star2 Stars3 Stars4 Stars5 Stars (17 votes, average: 3.00 out of 5)
Loading...



Leave a Reply